Brief ReportsLipid-Lowering Therapy and Long-Term Survival in Heart Transplantation
References (13)
- et al.
Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study
J Am Coll Cardiol
(1995) - et al.
Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings
J Am Coll Cardiol
(1988) - et al.
Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts
J Heart Transplant
(1990) - et al.
Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient
Circulation
(1987) - et al.
Cardiac allograft vasculopathy: current concepts
Am Heart J
(1995) Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound
J Heart Lung Transplant
(1995)
Cited by (20)
Proliferation signal inhibitors: Chemical, biologic, and clinical properties
2005, Transplantation ReviewsIntravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation
2005, Journal of the American College of CardiologyTreatment of hyperlipidemia in cardiac transplant recipients
2004, American Heart JournalCitation Excerpt :When a fibrate is deemed appropriate in a given patient, 600 mg of gemfibrozil daily should be used preferentially, although 54 mg of fenofibrate daily may be used as an alternative. Gemfibrozil is generic, less expensive than fenofibrate, has less reported nephrotoxicity, and has been associated with improved survival rates in CT recipients in a non-randomized trial.40 Fenofibrate has a slightly higher rate of nephrotoxicity when used with cyclosporine, but may have decreased pharmokinetic effects on statins as compared with gemfibrozil and appears to be better tolerated by some patients.
Cardiac allograft vasculopathy: Prevention and treatment options
2002, Transplantation ProceedingsImpact of lipid abnormalities in development and progression of transplant coronary disease: A serial intravascular ultrasound study
2001, Journal of the American College of CardiologyCitation Excerpt :Further, in a subgroup of patients, intracoronary ultrasound measurements at baseline and one year after transplantation showed less progression in maximal intimal thickness with pravastatin treatment. Two other investigations have confirmed the survival benefit of cholesterol lowering in transplant recipients (7,8). Our study underscores the importance of change in lipid values on progression of transplant vasculopathy.
Management of selected lipid abnormalities: Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation
2001, Cardiology ClinicsCitation Excerpt :Most heart transplant patients are also hyperlipidemic,16 and there may be an association between hyperlipidemia and development of accelerated cardiac graft vasculopathy,16,28 although Lp(a) levels do not appear to be a risk factor.28 Lipid-lowering drug therapy appeared to confer a survival benefit in cardiac transplant patients who survive beyond the first year.110 Treatment of hyperlipidemia after heart transplant is advisable, and a Heart Transplant Lipid Registry has been formed to track outcomes in heart transplant recipients relative to lipid management.15